Safety, Efficacy, and Durability of Outcomes: Results from SECURE: A Single Arm, Multicenter, Prospective, Clinical Study on a Minimally Invasive Posterior Sacroiliac Fusion Allograft Implant
DOI: https://doi.org/10.2147/jpr.s458334
IF: 2.8319
2024-03-19
Journal of Pain Research
Abstract:Aaron Calodney, 1 Nomen Azeem, 2 Patrick Buchanan, 3 Ioannis Skaribas, 4 Ajay Antony, 5 Christopher Kim, 6 George Girardi, 7 Chau Vu, 8 Christopher Bovinet, 9 Rainer Vogel, 10 Sean Li, 11 Navdeep Jassal, 12 Youssef Josephson, 13 Timothy Lubenow, 14 Christopher M Lam, 15 Timothy R Deer 6 1 Precision Spine Care, Tyler, TX, USA; 2 Florida Spine and Pain Specialists, Tampa, FL, USA; 3 Spanish Hills Interventional Pain Specialists, Camarillo, CA, USA; 4 Expert Pain P.A, Houston, TX, USA; 5 The Orthopaedic Institute, Gainesville, FL, USA; 6 The Spine and Nerve Center, Charleston, WV, USA; 7 Front Range Pain Medicine, Fort Collins, CO, USA; 8 Evolve Restoration Center, Santa Rosa, CA, USA; 9 The Spine Center of Southeast Georgia, Brunswick, GA, USA; 10 Comprehensive and Interventional Pain Management, Henderson, NV, USA; 11 Premier Pain Centers, Shrewsbury, NJ, USA; 12 Excel Pain and Spine, Lakeland, FL, USA; 13 The Pain Management Center, Voorhees Township, NJ, USA; 14 Rush University Medical Center, Chicago, IL, USA; 15 University of Kansas Medical Center, Kansas City, KS, USA Correspondence: Aaron Calodney, Precision Spine Care, Tyler, TX, USA, Email Introduction: Research suggests that sacroiliac joint (SIJ) dysfunction is responsible for 15% to 30% of reported low back pain cases. Recently, there has been an increasing interest in SIJ fusion using minimally invasive surgery (MIS) due to safety. Initially, devices designed for MIS were intended for lateral approaches. A minimally invasive sacroiliac fusion implant for use with a posterior approach has been developed and is regulated for clinical use under the regulatory framework required for human cells, tissues, or cellular or tissue-based products (HCT/Ps). Methods: A multi-center, prospective, single-arm study was launched after initial studies provided preliminary data to support safety, efficacy, and durability of this minimally invasive sacroiliac posterior fusion LinQ allograft implant (NCT04423120). Preliminary results were reported previously. Final results for the full participant cohort are presented here. Results: One-hundred and fifty-nine (159) participants were enrolled across 16 investigational sites in the US between January 2020 and March 2022. One-hundred and twenty-two (122) participants were implanted. At the 1-month follow-up, 82 participants satisfied all criteria for the composite responder endpoint, representing 73.2% of the study cohort. These results stayed consistent across the remaining study timepoints with 66.0%, 74.4%, and 73.5% of participants classified as responders at the 3-, 6- and 12-month follow-up visits, respectively. VAS scores were significantly reduced (p < 0.0001) and ODI scores were significantly improved (p < 0.0001). All domains of the PROMIS-29 were also significantly improved (all p's < 0.0001). Only one procedure-related serious AE was reported in the study. Conclusion: These results suggest that the posterior approach LinQ Implant System is a safe and effective treatment for sacroiliac joint dysfunction at 12 months, with results that are favorable compared to outcomes reported for an FDA-cleared lateral approach. Keywords: sacroiliac joint disease, sacroiliac fusion, single point posterior fusion, back pain, minimally invasive spine surgery, sacroiliitis Low back pain continues to be an escalating cause of disability on both a national and international scale. The Lancet published a study in 2017 that examined the incidence, prevalence, and years lived with disability for 328 diseases in 195 countries. This study found that low back pain accounted for over 57 million years of living with disability, representing an 18% increase from 2006 to 2016 in the countries surveyed. 1 Research suggests that sacroiliac joint (SIJ) dysfunction is responsible for 15% to 30% of reported low back pain cases. 2–4 Traditional SIJ dysfunction treatments involve medications, therapy, injections, and ablations. 3 In cases where these methods fail, surgical fixation is considered. Recently, there has been an increasing interest in SIJ fusion using minimally invasive surgery (MIS), due to its lower associated complication rates, including estimated blood loss (EBL), operative time, and length of stay (LOS) compared to open fusion. 5 A retrospective study comparing open surgery and MIS for SIJ dysfunction at a single institution found statistically significant reductions in EBL (681 mL v 41 m -Abstract Truncated-
clinical neurology